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ABSTRACT: We review the original rationale for the development and the chemistry of
a series of new synthetic oleanane triterpenoids (SO), based on oleanolic acid (1)a sa
starting material. Many of the new compounds that have been made, such as 2-cyano-3,12-
dioxooleana-1,9(11)-dien-28-oic acid (“CDDO”, 8), are highly potent (activities found at
levels below 1 nM) anti-inﬂammatory agents, as measured by their ability to block the
cellular synthesis of the enzyme inducible nitric oxide synthase (iNOS) in activated
macrophages. Details of the organic synthesis of new SO and their chemical mechanisms of biological activity are reviewed, as is
formation of biotin conjugates for investigation of protein targets. Finally, we give a brief summary of important biological activities
of SO in many organ systems in numerous animal models. Clinical investigation of a new SO (methyl 2-cyano-3,12-dioxooleana-
1,9(11)dien-28-oate, “CDDO-Me”, bardoxolone methyl, 13) is currently in progress.
’INTRODUCTION
Cellularlifearoseinanextremelyhostilechemicalenvironment,
with abundant electrophilic stress provided by reactive species of
oxygen (ROS) and nitrogen (RNS) in the primitive biosphere.
Mechanisms to protect our ancient genome from electrophilic
damage,named“electrophilecounterattack”byTalalay,
1 had high
evolutionary survival value, and it is therefore not surprising that
the genome evolved new mechanisms to protect itself from
oxidative, nitrosative, or other mutagenic damage. Enzymes of
DNA repair are perhaps the best known examples.
The ancient incorporation of mitochondria into cellular eukar-
yotic life allowed a great leap in cellular energetics, enabling
organisms to become actively motile in their quest for nutrients.
However, oxidative processes in the mitochondrion also have the
capacitytogeneratereactivespeciesofoxygenthatcandamagethe
genome, as well as proteins and lipids, in cells.
2 With the evolu-
tionary development of the immune system, both macrophages
and neutrophils arose; these cells generate reactive species of both
oxygenandnitrogeninordertokillforeignpathogens.
3Asaresult,
as an undesirable side eﬀect, the rest of the cells in the body as a
wholecouldthensuﬀerfurtherdamagefromthesereactivespecies.
Thus, although ROS and RNS indeed have powerful ability to kill
invading microorganisms, they also have potential for damaging
cellular DNA, as well as cellular proteins and lipids. As a con-
sequence,betweenthemitochondriafoundinessentiallyallanimal
cellsthatenableustoleadanactiveandthinkinglifeandthecellsof
theimmunesystemthataresoessentialtoprotectusfrominvading
microorganisms, our bodies have great potential to damage
themselves. Metabolic stress caused by ingestion of undesirable
xenobiotics has added yet another layer of tissue damage.
4
It is therefore not surprising that mechanisms evolved to
protect the organism from both endogenous and exogenous
damagetoDNAandproteins,becauseoftheirsurvivalvalue.The
purine and pyrimidine bases of DNA are particularly vulnerable
targets of reactive oxygen and nitrogen, but the highly reactive
cysteine proteome of the cell also requires protection from
oxidative or inﬂammatory stress.
5 Many of the phosphorylating
kinases and dephosphorylating phosphatases of the cell have
reactivecysteinesattheircatalyticallyactivesites,
6andthesesites
are particularly vulnerable to damage.
In this review we will not discuss enzymes or enzymatic
mechanisms that repair DNA and drugs that interact with these
enzymes. Instead, we will focus on a set of drugs, namely,
synthetic oleanane triterpenoids (SO), that are highly potent
agents for promoting the cellular control of reactive oxygen and
nitrogen, as well as other chemical species that can damage both
DNA and proteins. SO are potent agents for suppressing either
the undesirable formation of both ROS and RNS or the
deleterious electrophilic actions of both ROS and RNS. In
experimental animal studies, SO can protect many organs of
the body from such damage. Moreover, SO show great promise
as practical therapeutic agents, especially with the recent clinical
advances in the use of one such agent (methyl 2-cyano-3,12-
dioxooleana-1,9(11)dien-28-oate, 13; “CDDO-methyl ester” or
“CDDO-Me”;itsnewgenericnameis“bardoxolonemethyl”)for
treatment of a hitherto refractory serious disease, namely,
chronic kidney disease (diabetic nephropathy). It is therefore
appropriate to review the underlying assumptions, both biologi-
calandchemical,thatrelate toboth theeﬃcacyandsafetyofSO.
Oursyntheticeﬀortsbeganasanattempttodesignnewagents
with potent anti-inﬂammatory activity. In addition to the
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established classic role of inﬂammation as a causative factor in
diseases such as rheumatoid arthritis or chronic lung and kidney
disease, it was postulated more than 100 years ago that inﬂamma-
tion was an important process in the etiology of cancer,
7 and more
recently there has been greatinterest in the role of inﬂammationin
the genesis of both cardiovascular and neurodegenerative disease.
8
When we started this project in 1995, the naturally occurring
triterpenoids oleanolic acid (1) and ursolic acid (2)w e r ea l r e a d y
knowntohaveanticarcinogenicactivityinexperimentalanimals.
9,10
Both compounds were readily and cheaply available for further
synthetic modiﬁcations. As quantitative assays for evaluating the
eﬃcacyofnewmolecules,wechosetomeasuretheirabilitytoblock
the cellular synthesis of an enzyme that plays a key role in the
process of inﬂammation, namely, inducible nitric oxide synthase
(iNOS).
11 This enzyme is responsible for high-level synthesis of
NO from arginine, especially in macrophages, which play a critical
role in inﬂammation throughout the body. The bioassays that we
have used to evaluate the new synthetic compounds are easily
performed, rapid, and quantitative, thus providing a good basis for
establishing structure-activity relationships.
In the present review, we discuss the original chemical
synthesis of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid
(“CDDO”, 8) and its related analogues and the chemistry of
triterpenoid biogenesis from squalene and review some of the
critical chemical parameters that are important for the selective
action and safety of SO. Special emphasis will be placed on the
rationale for synthetic chemical modiﬁcation of a naturally
occurring terpenoid scaﬀold, if we are to make safe and eﬀective
drugs. Important biological actions of the new SO and their
potentialclinicalapplicationswillbecoveredverybrieﬂy;thiswill
be the subject of a subsequent review.
’CHEMISTRY OF SYNTHETIC OLEANANE
TRITERPENOIDS
The biological importance of the triterpenoid skeleton is
almost without parallel among natural products. The annual
reviews of triterpenoids in Natural Product Reports are ample
testimony to the widespread distribution of these compounds in
our natural world, including squalenes, lanostanes, fusidanes,
dammaranes, euphanes, lupanes, oleananes, ursanes, hopanes,
tetranortriterpenoids, quassinoids, and others.
12 Within each
class are a dazzling array of structural diversity and a wide range
of biological activity.
Wechose tostudytheoleananeandursane classes, typiﬁedby
oleanolic acid (1) and ursolic acid (2), which are commercially
available and occur in many natural sources.
13 Some of these
representative triterpenoids are shown below.
The extensive pharmacology of oleanolic acid (1) and ursolic
acid (2) has been reviewed.
13-15 Although the biological activity
of1and2ismodest,oleanolicacidhasbeenmarketedinChinaas
an oral drug for treating liver disorders in humans.
14 Moreover,
both 1 and 2 are well recognized to possess anti-inﬂammatory and
antitumor activities in animals. As the author of this 1995 review
states, “more research is warranted to develop a therapy for
patients”.
14 Coincidently, it was 1995 when we began this project.
Oursyntheticplanwastomodifythethree“active”portionsof
1 and 2, namely, the C-3 hydroxy, the ring C double bond (C-
12-C-13), and the C-28 carboxylic acid. In addition, various
ring-cleavage reactions were envisioned to lead to promising
syntheticanaloguesforscreening.ThisissummarizedinFigure1
for oleanolic acid.
Following the synthesis and screening of some 70 oleanolic
andursolicacidderivatives,ourﬁrst“hit”intheiNOSassaycame
when the A-ring enone 3 was prepared.
16 This compound was
the 46th synthetic triterpenoid prepared in our laboratory (“TP-
46”) and was signiﬁcantly active in the iNOS assay we used, with
IC50 6.0 μM. The corresponding ursolic acids, TP-47 (4) (IC50
17.6 μM) and TP-81 (6), are uniformly less active. This
prompted us to convert the C-ring to its corresponding enone.
Indeed, compound TP-82 (7) with both rings similarly trans-
formed displayed an increase in potency with an IC50 of 0.2 μM.
Interestingly,theisomericbis-enoneTP-72(5)islessactivethan
TP-82 (7). With these encouraging and leading results, we
considered that ring-A substitution at C-2 with an electron-
withdrawing group would further activate ring A to a conjugate
addition reaction (e.g., a thio- or aza-Michael reaction) since this
mechanistic pathway seemed plausible for a biological mode of
action. Indeed, TP-151 (“CDDO”) (2-cyano-3,12-dioxooleana-
1,9(11)-dien-28-oic acid) (8), with a C-2 cyano group, markedly
increasedtheactivitybyabout10000-foldoverthatofTP-46(3)
and is approximately 400000 times more potent than oleanolic
acidintheiNOSassay.
11Thestructure-activity proﬁleisshown
in Figure 2.
Although the rigid scaﬀold of the oleanane-ursane
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is that the two functionalized carbons in OA and UA, C-3
and C-28, are of the neopentyl type [(CH3)3CCH2-].
Thus, the geminal methyl groups on C-4 and the D-Er i n g
fusion surrounding C-28 severely limit the reactivity of these
positions to nucleophilic attack (e.g., SN2 reactions). It is well
known that neopentyl halides are markedly unreactive in SN2
reactions (Table 1) due to the diﬃculty of approach by the
nucleophile to the backside of the carbon-leaving group
bond.
The lack of reactivity of neopentyl systems is illustrated
dramatically by the conditions necessary to convert the neopen-
tyl nosylate 9 to 10: a 300-fold excess of sodium cyanide in
DMSO at 115 C for 12 h.
17 This fact would seem to limit
side reactions at C-3 and C-28 with extraneous cellular
nucleophiles.
Illustrative of the “protected” reactivity of C-3 and C-28 to
nucleophilic attack is the fact that our attempts to displace the
C-3 mesylate (11) prepared from OA under classic SN2 condi-
tions with sodium azide (DMF, 100 C) resulted in E2 elimina-
tion to give 12 rather than substitution, and reaction of 11 with
lithium bromide in boiling acetone led to recovered starting
Figure 1. Proposed structural modiﬁcations of oleanolic acid.
Figure 2. Summary of structure-activity relationships of lead compounds and CDDO (8).
Table 1. Average Relative Rates of Alkyl Halides with
Nucleophiles
a
alkyl relative rate
methyl 30
ethyl 1.0
propyl 0.4
isopropyl 0.025
neopentyl 0.00001
aCompiled from several studies; see ref 17.540 dx.doi.org/10.1021/np100826q |J. Nat. Prod. 2011, 74, 537–545
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material. Likewise, hydrolysis of the C-28 methyl ester 13 (TP-
155, CDDO-Me) to give CDDO (8) could not be accomplished
under conventional saponiﬁcation conditions, but required
roundabout nucleophilic attack by lithium iodide on the methyl
group (vide infra). Similarly, the extremely biologically active
CDDO-Im (14) (TP-235) is relatively stable to N-acyl nucleo-
philic cleavage, unlike typical N-acylimidazoles, once again
indicative of the neopentyl nature of C-28. The acid chloride
of CDDO that was used to synthesize CDDO-Im (14)i s
remarkably stable to nucleophilic addition reactions compared
to typical acid chlorides.
18
Moreover, the high electrophilic reactivity of the A-ring
cyanoenone (vide infra) is also reﬂected in the high reversibility
of the thio-Michael adduct, which also precludes irreversible
conjugate addition reactions (e.g., aza-Michael reactions) with
cellular amine and other nucleophiles and presumed accompa-
nying toxicity. We view the unique biological activity of CDDO
andrelated triterpenoidcyanoenonesastheresultofa“dock and
lock”processwithacysteineand/orotheraminoacidresiduesof
target proteins. Indeed, as shown above, the enhanced activity of
the oleanane scaﬀold over the ursane scaﬀold, where the only
diﬀerence is the position of the two methyl groups in ring E,
would suggest more favorable target docking for the former
derivatives.
Synthesis of CDDO-Me (13) and CDDO (8). The synthesis
of CDDO (8)features a two-stage modification of the C-ring
andA-ringandisachievedin11stepsfromoleanolicacid(1),
in an 29% overall yield (Scheme 1).
16,18 Initial regioselective
esterification of the C-28 carboxylic acid using diazomethane
followed by acylation of the C-3 hydroxy group afforded
diester 15. Epoxidation of 15 using hydrogen peroxide
followedbyinsituacid-mediatedepoxiderearrangementgave
the C-12 ketone 16. A sequence of bromination/dehydro-
bromination of ketone 16 provided enone 17 and thus the
desired C-ring elaboration. Alkaline hydrolysis released the
C-3hydroxygroup,whichwasfollowedbyJonesoxidationto
givediketone19.Formylation of 19with ethyl formate in the
presence of sodium methoxide in benzene provided inter-
mediate 20. Isoxazole 21 was synthesized from 20 by con-
densationwithhydroxylamine.Cleavageofisoxazole21using
s o d i u mm e t h o x i d eg a v en i t r i l e22, predominantly as the enol
tautomer shown. Oxidation with DDQ gave the correspond-
ingbis-enoneCDDO-Me(13)(TP-155).Finalhalogenolysis
with lithium iodide in dimethylformamide afforded CDDO
(8) (TP-151).
This synthesis has been further modiﬁed for large-scale commer-
cial drug development, and it is now possible to produce CDDO-
Me (bardoxolone methyl, 13) in multiple kilogram amounts.
The olive tree, both its fruit and its leaves, provides a widely
available, commercially reasonable source of oleanolic acid (1).
Biosynthesis of Olean-12-ene and Urs-12-ene Skeletons.
As summarized in Scheme 2, the cyclization of 2,3-oxidosqualene
(24) into sterols and other triterpenes is one of the most
remarkable and fascinating biotransformations found in
nature.
19-22 The construction of tetra- and pentacyclic carbon
frameworks catalyzed by oxidosqualene cyclases (OSCs) estab-
lishes a number of asymmetric stereocenters [eight chiral centers
inthecyclizationof2,3-oxidosqualene(24)toβ-amyrin(29)]ina
single biotransformation. The chair-chair-chair-boat confor-
mation of 24 initiates the formation of β-amyrin and provides
dammarenyl cation (25), which is followed by ring expansion to
give the baccharenyl cation (26). Electrophilic addition of the
tetracyclicbaccharenylcation(26)ontotheterminaldoublebond
generates the lupenyl cation (27) with the creation of a five-
membered E-ring. The corresponding oleanyl secondary cation
(28) is thus obtained from the lupenyl cation (27) through the
E-ringexpansionwiththereliefofringstrainbythegenerationofa
six-memberedE-ring,despitethenormallyunfavorablegeneration
of a secondary cation from a tertiary carbocation. Finally, two
sequential 1,2-hydride shifts followed by H-12R elimination yield
β-amyrin (29) with a 6/6/6/6/6-fused ring system. Alternatively,
a C-29 methyl shift indicated by pathway “b” generates the ursyl
C-20 cation (32)f r o mt h eo l e a n y lc a t i o n( 28). Three sequential
1,2-hydride shiftsfollowed by H-12R elimination afford R-amyrin
(31), which can also be obtained from the bisnoroleanyl C-20
cation (30) through a sequential methyl shift and two hydride
shifts followed by H-12R elimination.
21 Electrophilic addition of
thebaccharenylcation(26)generates30withthecreationofasix-
membered E-ring and a secondary carbocation, rather than a five-
membered E-ring and a tertiary carbocation.
’CHEMICAL MECHANISMS OF BIOLOGICAL ACTIVITY
The construction of a 1-en-3-one moiety in the A-ring of
oleanolic acid imparts tremendous biological activity compared
to what is conveyed by the natural oleanane scaﬀold. Further-
more, the installation of certain electron-withdrawing groups at
the C-2 position (e.g., carboxyl, nitrile) ampliﬁes the potency of
this triterpenoid.
18 As a result, we postulate that the biological
mechanism of action involves nucleophilic attack (thio- or aza-
Michael addition) of a thiol or other nucleophile to the C-1
position (Scheme 3). The signiﬁcance of thio-Michael addition
reactions in biological systems has been reported recently,
including the fact that these reactions can be reversible.
23-26
Moreover, hetero-Michael reactions (e.g., thio-, aza-, and oxa-
Michael reactions) are assuming enormous importance in or-
ganic synthesis.
27-29
Surprisingly, our attempted reactions of CDDO (8) with
various thiol and amine nucleophiles failed to aﬀord isolable
addition products.
30 Spectroscopic (UV-vis) studies of CDDO
in the presence of either reduced glutathione (GSH) or dithio-
threitol (DTT), as sulfur nucleophiles, revealed changes in the
observed absorption peaks, indicatingreactionsbetweenCDDO
and GSH or DTT, but isolable adducts were not obtained.
30
These observations are supported by NMR studies that showed
the expected reversible conjugate addition of sulfur nucleophiles
to C-1 of CDDO to give products, such as 33, wherein the C-1541 dx.doi.org/10.1021/np100826q |J. Nat. Prod. 2011, 74, 537–545
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vinyl proton is no longer present, similar to the NMR spectrum
of comparison compound 34.
31 Thus, temperature studies have
revealed that the A-ring cyanoenone in CDDO is quite reactive
to nucleophilic attack; however, these in situ formed adducts are
readily reversible upon raising the temperature.
30
While an irreversible Michael acceptor might be more biolo-
gicallypotent,thereversiblenatureofCDDOshouldenhanceits
bioavailabilitytotargetproteins.
22WeconsiderthattheA-ringin
CDDO might be further activated toward conjugate addition by
other interactions with a target protein in vivo. Studies designed
to isolate intermediate CDDO-like adducts are currently under-
way in our laboratory.
’BIOTIN CONJUGATES
InordertodevelopmorepotentCDDOanalogues,weobviously
needmoreinformationaboutthemechanismofactionandweneed
to identify target proteins. The aﬃnity chromatographic technique
of biotinylation is an important molecular tactic for identifying target
proteins.
32 After a biotinylated drug molecule docks with a target
protein, the biotin moiety can be complexed with immobilized
streptavidin and subsequently isolated and puriﬁed. Toward this goal
wedesignedandsynthesizedthebiotin-CDDOconjugate35,which
was found to be only 3-10 times less potent than CDDO (8).
33
Multiple target proteins have now been identiﬁed with this biotiny-
lated probe. Moreover, it has been used in a proteomics study
(unpublished data) that has shown this compound can selectively
bind to many diﬀerent proteins in the cell with high aﬃnity.
’A GENERAL OVERVIEW OF STRUCTURE-ACTIVITY
RELATIONSHIPS
Figure 3 summarizes the overall biological activity of hundreds of
new SO we have synthesized, as measured in our iNOS assay for
inhibition of induction of iNOS. It is important to emphasize that a
Scheme 1. Synthesis of CDDO-Me (13) and CDDO (8)542 dx.doi.org/10.1021/np100826q |J. Nat. Prod. 2011, 74, 537–545
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totally diﬀerent bioassay might yield a diﬀerent SAR proﬁle, but this
hasnotyetbeenperformedinacomprehensivemanner.However,in
general, measured activities in antiproliferative assays and apoptosis
assays correlate with those found in the iNOS assay.
’BIOLOGICAL ACTIVITIES OF SYNTHETIC OLEANANE
TRITERPENOIDS
As noted in the Introduction, the original rationale for
synthesis of new SO relied on their ability to suppress
inﬂammation. This was ﬁrst measured by their inhibition of the
inductionoftheenzymeiNOS,whoseexpressionisstimulatedin
cell cultures by various inﬂammatory cytokines, such as inter-
feron gamma (IFN-γ), tumor necrosis factor-alpha (TNF-R),
andinterleukin-1(IL-1).ItshouldbeemphasizedthatSOarenot
direct enzyme inhibitors themselves, but rather they block the
ability of inﬂammatory cytokines to induce transcription of the
respective iNOS gene.
11 In the original report of the biological
activity of CDDO (8), it was shown that SO also can induce cell
Scheme 2. Biosynthesis of the Oleanane and Ursane Skeletons
Scheme 3. Postulated Mechanism Involving a Thio-Michael Addition of Cysteine to CDDO (8)543 dx.doi.org/10.1021/np100826q |J. Nat. Prod. 2011, 74, 537–545
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diﬀerentiation and inhibit cell proliferation.
11 This was then
followed by several observations that SO are potent agents for
induction of apoptosis (programmed cell death, as opposed to
nonspeciﬁc cytotoxicity)
34-36 and are also strongly cytoprotec-
tive against various forms of electrophilic attack.
37,38 The cyto-
protective eﬀects are believed to be mediated by binding of the
SO to the inhibitory protein Keap1, which then releases its
partner, Nrf2, to be an active transcription factor for expression
of mRNA that codes for synthesis of a host of cytoprotective
molecules. These molecules include enzymes that directly de-
stroy ROS, as well as enzymes that synthesize small molecules
such as glutathione that scavenge potentially destructive electro-
philes. This action is known as the “phase 2 response” and has
also been called electrophile counterattack.
1,39 These overall
actions of SO were summarized in a deﬁnitive review written
in 2007.
40
Many protein targets of SO have already been identiﬁed. In
almost all cases, it has been shown that the binding of the SO to
its protein target involves an active cysteine residue in the target.
ThemechanismofsuchbindinginvolvesMichaeladdition,ashas
been discussed earlier in this review. Important protein targets
include Keap1,
37,38 I-kappa-B kinase (IKK),
41,42 JAK1 (and one
of its targets STAT3),
43-45 PTEN,
46 and proteins associated
with the actin-cytoskeleton of the cell.
47,48 Proteomic studies,
usingthebiotinylatedtriterpenoiddescribedabove,arecurrently
ongoing in our laboratory for further elucidation of additional
proteintargets.Itisimportant torecognizethatbindingofSOto
cysteine residues in speciﬁc proteins is both context-dependent
anddose-dependent.The nucleophilicityofthefree SHgroupin
cysteine in a protein is markedly inﬂuenced by neighboring
amino acids. Moreover, the unique stereochemistry of the
oleanane scaﬀold prevents SO from randomly alkylating protein
targets, as has been discussed previously in this review. Thus,
many of the SO that have been synthesized sofar have extremely
favorable therapeutic actions in animal studies, with minimal
toxicity observed. In general, anti-inﬂammatory and cytoprotec-
tiveresponsestoSOarefavoredbyverylowconcentrations(low
nanomolar) of drug, while higher doses (high nanomolar to low
micromolar) of SO can even induce oxidative stress and
apoptosis.
38,40
Given the versatility of the SO, in terms of both their
mechanism of action described above and their safety, it is not
surprising that this class of agents has been extremely useful in
prevention or treatment of many diseases in experimental
animals, particularly those in which oxidative and inﬂammatory
stress plays a key role in pathogenesis.
8 By now, there is a very
large experimental literature documenting such activities. The
following are some of the diseases in which SO have been used
favorably in experimental animal models: several neurodegen-
erative diseases including Parkinson’s disease,
49 Huntington’s
disease,
49,50 and Alzheimer’s disease;
51 various inﬂammatory
diseases of the lung including cystic ﬁbrosis and emphysema
induced by cigarette smoke;
52-55 inﬂammatory cardiovascular
disease;
53,56acuteliverinjurycausedbycarcinogens,hepatotoxic
drugssuchasacetaminophen,orotheragents;
57-59diseasestates
characterized by hyperactivity of the immune system;
55-61
diseases of the retina and the uveal tract in the eye;
46,62 cancer,
including both prevention and treatment;
57-68 kidney injury
caused by toxic agents,
39,69 and most recently diabetes.
70
Thisimpressivelistofactivitiesinexperimentalanimalsmakes
it clear that clinical use in patients would be of major interest.
Thusfar,clinicalinvestigationsstillareintheirearlieststages,but
ithasalreadybeenshownthatCDDOmethylester(bardoxolone
methyl, 13) has yielded beneﬁcial results in patients with
advanced chronic kidney disease (CKD), many of whom suﬀer
from diabetic nephropathy. Promising results have already been
reportedinphase2trials,andalargephase3studyisplanned.As
is the case in many other diseases, the processes of oxidative and
inﬂammatory stress are believed to play a major role in the
pathogenesis of CKD, so there is a strong rationale for the use of
SO for this indication.
71 Thus far, CDDO methyl ester has been
very well tolerated in patients, and its clinical safety proﬁle
appears to be excellent. Again, these clinical ﬁndings suggest
that the use of a triterpenoid scaﬀold has greatly diminished the
potential for random alkylation that conceivably might occur
with the use of a drug that acts by Michael addition.
’CONCLUSIONS
Our very existence involves a trade-oﬀ between the require-
menttouse bothreactiveoxygenandnitrogen toprovideenergy
forlifeandprotectionfromdeathcausedbyinfectiousagentsand
the possibility that both reactive oxygen and nitrogen can also
causeirreparabledamagetotheorganism.Thus,lifetrulymadea
pact with the devil when it made a Faustian bargain and allowed
the mitochondrial genome into eukaryotic cells and a second
pact with the devil (another Faustian bargain) when it allowed
the development of the immune system. Of course, the immune
system can improve the quality of life, but it also can destroy the
organism, if it is not controlled. Both ROS and RNS are used at
extremely low concentrations within cells as essential mediators
of intracellular communication.
72 At much higher concentra-
tions, ROS and RNS produced by immune cells (macrophages,
Figure 3. Triterpenoid structure-activity relationships.544 dx.doi.org/10.1021/np100826q |J. Nat. Prod. 2011, 74, 537–545
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neutrophils, and lymphocytes) can eﬀectively destroy dangerous
invading microorganisms. Thus, it is essential that the body
tightly control the formation and activity of these molecules.
Indeed, research on oxidative, inﬂammatory, and metabolic
stress is now at center stage in biomedical research, with the
attendant development of new drugs to control such stress,
which is a cause of so many chronic degenerative diseases,
whether they be cardiovascular, pulmonary, arthritic, malignant,
neurodegenerative, renal, or other. Enhancement of the physio-
logical protective mechanisms that have evolved in our bodies
over many millennia now oﬀers unique opportunities to control
the pathogenesis of such diseases; the synthetic triterpenoids
oﬀer such possibility. Because of the unique steric hindrance of
the triterpenoid skeleton, triterpenoids provide a unique plat-
form for drug development. Each triterpenoid scaﬀold that
occurs in nature has its own stereochemistry of rings and
exocyclic methyl groups that convey speciﬁc recognition of
motifs in proteins in the cell. At the same time, this speciﬁc
stereochemistry prevents random contact of the triterpenoid
with all cellular proteins. Basic tetracyclic and pentacyclic triter-
penoid scaﬀolds also have unique safety proﬁles, because they
have been ingested safely by animals for millions of years. Here,
we have reviewed the striking progress that had already been
made with the new development of SO, but we have only
scratchedthesurface.Wecan beoptimisticthat further advances
will come that will provide relief from human physical suﬀering
and mental anguish.
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